In the case of a rapid and efficient implementation of the AV treatment protocol at the worldwide level, a delay of about 6 weeks would be obtained in the regions under study, a result that could be essential in gaining time to deploy vaccination campaigns targeting high-risk groups and essential services. In addition, the GLEaMviz tool provides simulated results for the number of AV drugs used during the evolution of the outbreak. If we assume treatment delivery and successful administration of the drugs to 30% of the symptomatic cases per day, the number of AV drugs required at the activity peak in Western Europe would be 4.5 courses per 1,000 persons, and the size of the stockpile needed after the first year since the start of the pandemic would be about 18% of the population. Again, we assume a homogeneous treatment protocol for all countries in the world; results may vary from country to country depending on the specific evolution of the pandemic at the national level.